Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Ratio (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Equity Ratio data on record, last reported at 0.87 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 4.92% year-over-year to 0.87; the TTM value through Sep 2025 reached 0.87, down 4.92%, while the annual FY2024 figure was 0.9, 0.37% changed from the prior year.
  • Equity Ratio reached 0.87 in Q3 2025 per VRDN's latest filing, down from 0.88 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.93 in Q3 2022 and bottomed at 0.84 in Q2 2022.
  • Average Equity Ratio over 5 years is 0.89, with a median of 0.9 recorded in 2024.
  • Peak YoY movement for Equity Ratio: skyrocketed 44.32% in 2021, then fell 7.08% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.92 in 2021, then fell by 1.46% to 0.91 in 2022, then decreased by 0.74% to 0.9 in 2023, then grew by 0.37% to 0.9 in 2024, then decreased by 3.67% to 0.87 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.87 in Q3 2025, 0.88 in Q2 2025, and 0.9 in Q4 2024.